Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort study

被引：0

作者：

Kanamori, Masayuki ^{[1
]}

Tsuzuki, Shunsuke ^{[2
]}

Shibahara, Ichiyo ^{[3
]}

Saito, Kuniaki ^{[4
]}

Shimoda, Yoshiteru ^{[1
]}

Tanaka, Kazuhiro ^{[5
]}

Yamaguchi, Shigeru ^{[6
]}

Natsumeda, Manabu ^{[7
]}

Matsutani, Tomoo ^{[8
]}

Hanihara, Mitsuto ^{[9
]}

Nakada, Mitsutoshi ^{[10
]}

Kuroda, Jun-Ichiro ^{[11
]}

Matsuda, Masahide ^{[12
]}

Yoshimoto, Koji ^{[13
]}

Yonezawa, Ushio ^{[14
]}

Sonoda, Yukihiko ^{[15
]}

Takano, Koji ^{[16
]}

Yonezawa, Hajime ^{[17
]}

Otani, Yoshihiro ^{[18
]}

Nakahara, Yukiko ^{[19
]}

Uchida, Masashi ^{[20
]}

Nonaka, Masahiro ^{[21
]}

Mineharu, Yohei ^{[22
]}

Kitamura, Yohei ^{[23
]}

Yamashita, Shinji ^{[24
]}

Yamauchi, Takahiro

Miyake, Yohei ^{[26
]}

Deguchi, Shoichi ^{[27
]}

Beppu, Takaaki ^{[28
]}

Tamura, Kaoru ^{[29
]}

Koizumi, Shinichiro ^{[30
]}

Hirose, Yuichi ^{[31
]}

Asano, Kenichiro ^{[32
]}

Hiruta, Ryo ^{[33
]}

Kinoshita, Manabu ^{[34
]}

Miyake, Keisuke ^{[35
]}

Nakayama, Noriyuki ^{[36
]}

Inoue, Akihiro ^{[37
]}

Ono, Takahiro ^{[38
]}

Sasaki, Takahiro ^{[39
]}

Akiyama, Yukinori ^{[40
]}

Fukami, Shinjiro ^{[41
]}

Yoshino, Atsuo ^{[42
]}

Kawanishi, Yu ^{[43
]}

Asanome, Taku ^{[44
]}

Yamaguchi, Takuhiro ^{[25
,45
]}

Takahashi, Masamichi ^{[46
]}

Yamasaki, Fumiyuki ^{[14
]}

Arakawa, Yoshiki ^{[22
]}

Narita, Yoshitaka ^{[46
]}

机构：

[1] Tohoku Univ, Grad Sch Med, Dept Neurosurg, 1-1 Seiryo Cho,Aoba Ku, Sendai, Japan

[2] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan

[3] Kitasato Univ, Sch Med, Dept Neurosurg, Sagamihara, Japan

[4] Kyorin Univ Facil Med, Dept Neurosurg, Tokyo, Japan

[5] Kobe Univ, Grad Sch Med, Dept Neurosurg, Kobe, Japan

[6] Hokkaido Univ, Fac Med, Dept Neurosurg, Sapporo, Japan

[7] Niigata Univ, Brain Res Inst, Dept Neurosurg, Niigata, Japan

[8] Chiba Univ, Grad Sch Med, Dept Neurol Surg, Chiba, Japan

[9] Univ Yamanashi, Dept Neurosurg, Yamanashi, Japan

[10] Kanazawa Univ, Dept Neurosurg, Kanazawa, Japan

[11] Kumamoto Univ, Fac Life Sci, Dept Neurosurg, Kumamoto, Japan

[12] Univ Tsukuba, Inst Med, Dept Neurosurg, Tsukuba, Japan

[13] Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Japan

[14] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan

[15] Yamagata Univ, Fac Med, Dept Neurosurg, Yamagata, Japan

[16] Osaka Int Canc Inst, Dept Neurosurg, Osaka, Japan

[17] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan

[18] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Okayama, Japan

[19] Saga Univ, Fac Med, Dept Neurosurg, Saga, Japan

[20] St Marianna Univ, Sch Med, Dept Neurosurg, Kawasaki, Kanagawa, Japan

[21] Kansai Med Univ, Dept Neurosurg, Hirakara, Japan

[22] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan

[23] Keio Univ, Sch Med, Dept Neurosurg, Tokyo, Japan

[24] Univ Miyazaki, Fac Med, Dept Clin Neurosci, Div Neurosurg, Miyazaki, Japan

[25] Univ Fukui, Fac Med Sci, Dept Neurosurg, Div Med, Fukui, Japan

[26] Yokohama City Univ, Grad Sch Med, Dept Neurosurg, Yokohama, Japan

[27] Shizuoka Canc Ctr, Div Neurosurg, Nagaizumi, Japan

[28] Iwate Med Univ, Dept Neurosurg, Shiwa, Japan

[29] Tokyo Med & Dent Univ, Dept Neurosurg, Tokyo, Japan

[30] Hamamatsu Univ, Sch Med, Dept Neurosurg, Hamamatsu, Japan

[31] Fujita Hlth Univ, Dept Neurosurg, Toyoake, Japan

[32] Hirosaki Univ, Grad Sch Med, Dept Neurosurg, Hirosaki, Japan

[33] Fukushima Med Univ, Dept Neurosurg, Fukushima, Japan

[34] Asahikawa Med Univ, Dept Neurosurg, Asahikawa, Hokkaido, Japan

[35] Kagawa Univ, Fac Med, Dept Neurol Surg, Kagawa, Japan

[36] Gifu Univ, Grad Sch Med, Dept Neurosurg, Gifu, Japan

[37] Ehime Univ, Sch Med, Dept Neurosurg, Toon, Japan

[38] Akita Univ, Grad Sch Med, Dept Neurosurg, Akita, Japan

[39] Wakayama Med Univ, Sch Med, Dept Neurol Surg, Wakayama, Japan

[40] Sapporo Med Univ, Dept Neurosurg, Sapporo, Japan

[41] Tokyo Med Univ, Dept Neurosurg, Tokyo, Japan

[42] Nihon Univ, Sch Med, Dept Neurol Surg, Tokyo, Japan

[43] Kochi Univ, Kochi Med Sch, Dept Neurosurg, Kochi, Japan

[44] Nakamura Mem Hosp, Brain Tumor Ctr, Dept Neurosurg, Sapporo, Japan

[45] Tohoku Univ, Grad Sch Med, Div Biostat, Sendai, Japan

[46] Natl Canc Ctr, Dept Neurosurg & Neurooncol, Tokyo, Japan

来源：

NEURO-ONCOLOGY ADVANCES | 2024年 / 6卷 / 01期

关键词：

Asian population; determinant of use; glioblastoma; survival; tumor-treating fields; PHASE-II; TEMOZOLOMIDE; CHEMOTHERAPY; RESECTION; EFFICACY; CRITERIA; EXTENT; TRIAL; WAFER;

D O I：

10.1093/noajnl/vdae176

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. The EF-14 clinical trial demonstrated the safety and efficacy of tumor-treating fields (TTFields) for newly diagnosed glioblastoma. This study aimed to clarify the current status, safety, and efficacy of TTFields in Japanese patients who meet the EF-14 inclusion criteria. Methods. This was a multicenter retrospective cohort study. Background, treatment, and outcome data of patients who satisfied the inclusion criteria of the EF-14 trial were collected from 45 institutions across Japan. The rate, determinants, and current status of TTField use, including its safety and efficacy in terms of progression and survival, were retrospectively investigated. This study was conducted in accordance with the STROBE checklist. Results. Among the 607 patients enrolled, 70 were excluded due to progressive disease during radiation and temozolomide therapy, age > 80 years old, and Karnofsky Performance Status score of <70. Among the remaining 537 patients, 210 (39%) underwent TTField treatment. Multivariate analysis revealed younger age and spouse as a caregiver as significant factors for TTField use. The compliance rate of TTField use exceeded 75% in 60% of patients, with a median TTField usage duration of 11 months. Skin disorders requiring medical treatment occurred in 56% of patients. Multivariate Cox proportional hazards analysis in the whole series and propensity score-matched analysis revealed that TTField use was not a prognostic factor for progression-free survival (PFS) or overall survival (OS). Conclusions. TTField use did not have a substantial effect on either PFS or OS in Japanese patients with glioblastoma, despite compliance rates comparable to those observed in the EF-14.

引用

页数：11

共 50 条

[21] Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study
Bokstein, Felix
Blumenthal, Deborah
Limon, Dror
Ben Harosh, Carmit
Ram, Zvi
Grossman, Rachel
FRONTIERS IN ONCOLOGY, 2020, 10
[22] Phase 1 study of concomitant tumor treating fields and temozolomide chemoradiation for newly diagnosed glioblastoma
Goldlust, Samuel A.
Singer, Samuel
Cappello, Lori A.
AlMekkawi, Ahmad K.
Lee, Kangmin D.
Ingenito, Anthony C.
Lewis, Brett E.
Nyirenda, Themba
Azmi, Hooman
Kaptain, George J.
NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
[23] Antiepileptic treatment and survival in newly diagnosed glioblastoma patients: Retrospective multicentre study in 285 Italian patients
Rigamonti, Andrea
Imbesi, Francesca
Silvani, Antonio
Gaviani, Paola
Agostoni, Elio
Porcu, Luca
De Simone, Irene
Torri, Valter
Salmaggi, Andrea
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 390 : 14 - 19
[24] Impact of postoperative dexamethasone on survival, steroid dependency, and infections in newly diagnosed glioblastoma patients
Mistry, Akshitkumar M.
Jonathan, Sumeeth, V
Monsour, Meredith A.
Mobley, Bret C.
Clark, Stephen W.
Moots, Paul L.
NEURO-ONCOLOGY PRACTICE, 2021, 8 (05) : 589 - 600
[25] Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields
Aaron Michael Rulseh
Jiří Keller
Jan Klener
Jan Šroubek
Vladimír Dbalý
Martin Syrůček
František Tovaryš
Josef Vymazal
World Journal of Surgical Oncology, 10
[26] Application of tumor treating fields for newly diagnosed glioblastoma: understanding of nationwide practice patterns
Shearwood McClelland
Oluwadamilola Sosanya
Timur Mitin
Catherine Degnin
Yiyi Chen
Albert Attia
John H. Suh
Jerry J. Jaboin
Journal of Neuro-Oncology, 2018, 140 : 155 - 158
[27] Treatment outcomes in glioblastoma patients aged 76 years or older: a multicenter retrospective cohort study
Uzuka, Takeo
Asano, Kenichiro
Sasajima, Toshio
Sakurada, Kaori
Kumabe, Toshihiro
Beppu, Takaaki
Ichikawa, Masahiro
Kitanaka, Chifumi
Aoki, Hiroshi
Saito, Kiyoshi
Ogasawara, Kuniaki
Tominaga, Teiji
Mizoi, Kazuo
Ohkuma, Hiroki
Fujii, Yukihiko
Kayama, Takamasa
JOURNAL OF NEURO-ONCOLOGY, 2014, 116 (02) : 299 - 306
[28] Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
She, Lei
Gong, Xuan
Su, Lin
Liu, Chao
ONCOLOGIST, 2023, 28 (01) : E45 - E53
[29] Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis
Matthew T. Ballo
Patrick Conlon
Gitit Lavy-Shahaf
Adrian Kinzel
Josef Vymazal
Aaron M. Rulseh
Journal of Neuro-Oncology, 2023, 164 : 1 - 9
[30] Survival impact of delaying postoperative chemoradiotherapy in newly-diagnosed glioblastoma patients
Zhang, Maochen
Xu, Fei
Ni, Weiqiong
Qi, Weixiang
Cao, Weiguo
Xu, Cheng
Chen, Jiayi
Gao, Yunsheng
TRANSLATIONAL CANCER RESEARCH, 2020, 9 (09) : 5450 - 5458

← 1 2 3 4 5 →